-

Acerus Announces Resignation of Norma Beauchamp As Director

TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) announced that Norma Beauchamp has resigned as a member of the Company's Board of Directors. The Acerus team and the Company’s Board of Directors thank Ms. Beauchamp for her contribution and commitment to the Company since joining the Board of Directors in 2015 and wish her well in all her future endeavors.

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. The Company commercializes its products via its own salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Contacts

Edward Gudaitis
President and Chief Executive Officer
egudaitis@aceruspharma.com
(905) 817-8194

Industry:

Acerus Pharmaceuticals Corporation

TSX:ASP
Release Versions
English

Contacts

Edward Gudaitis
President and Chief Executive Officer
egudaitis@aceruspharma.com
(905) 817-8194

Social Media Profiles
Acerus Pharma LinkedIn
More News From Acerus Pharmaceuticals Corporation

Acerus Announces Waiver of Q4 Financial Covenant in Credit Agreement

TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP, OTCQB: ASPCF) today announced that it received a waiver letter from SWK Funding LLC (“SWK”) related to the required Minimum Revenue Covenant for Q4-2020 in its existing credit facility with Acerus. All other terms and conditions in the SWK loan agreement remain unchanged. About Acerus Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercial...

Acerus Announces Details of Previously Completed Rights Offering

TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP, OTCQB: ASPCF) is pleased to announce that, further to its press release dated November 25, 2020 with respect to the completion of Acerus’ rights offering (the “Rights Offering”), Acerus issued 526,600,000 common shares of Acerus (“Common Shares”) under the Rights Offering at a price of $0.025 per share for gross proceeds of approximately $13,165,000. The Rights Offering was over-subscribed by $48...

Acerus Announces Completion of Over-Subscribed Rights Offering

TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP, OTCQB: ASPCF) is pleased to announce the completion of its rights offering (the “Rights Offering”), which expired at 5:00 pm (EST) on November 24, 2020. The Rights Offering was over-subscribed and will result in the issuance of 526,600,000 common shares of Acerus at a price of $0.025 per share for gross proceeds of approximately $13,165,000. Although Acerus had a standby commitment in place with...
Back to Newsroom